Cellceutix Abstract Accepted by AACR

BEVERLY, MA--(Marketwire - March 15, 2010) - Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced that the American Association for Cancer Research (AACR) has accepted an abstract of data on Kevetrin for presentation at its 101st Annual Meeting from April 17th to 22nd in Washington, DC. This abstract titled "Novel small molecule has potent anti-tumor activity in drug resistant tumor xenograft models" contains data on Kevetrin that have not previously been made public. The abstract will be presented at a session entitled "Late-Breaking Research: Experimental and Molecular Therapeutics 2," on April 20.

"This is a significant event for Cellceutix," said its Chief Scientific Officer, Dr. Krishna Menon. "The AACR is the premier cancer research organization and its annual meeting attracts scientists and pharma executives throughout the world. We are pleased to be able to present our data at the upcoming meeting."

In animal studies, Kevetrin was found to significantly delay tumor growth in multi-drug resistant lung, breast and colon cancer cell lines. More information about these studies is available on the Cellceutix web site at www.cellceutix.com.

About Cellceutix

Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

Contact Information: Contact: Cellceutix Corp. Leo Ehrlich (978) 633-3623